UK-based Actimed Therapeutics Ltd has appointed Robin Bhattacherjee as chief executive to help the company drive development of its lead product for cancer-related cachexia. Mr Bhattacherjee joins from Actelion, part of the Johnson & Johnson group of companies, where he was general manager for the UK and Ireland. He also served on the board of management of the UK industry association, ABPI. During his career, which started at Bayer AG, he has been involved in product launches in both the UK and Europe.
Actimed announced the appointment on 30 October 2019.